This trial is active, not recruiting.

Condition type 2 diabetes mellitus
Treatments met dr, met ir, placebo
Phase phase 2
Sponsor Elcelyx Therapeutics, Inc.
Start date September 2015
End date July 2016
Trial size 552 participants
Trial identifier NCT02526524, LCRM112


The purpose of the study is to compare the glycemic effects of delayed-release metformin (Met DR) to placebo in subjects with type 2 diabetes mellitus (T2DM) over 16 weeks. The study is designed to evaluate several doses of Met DR (600 to 1500 mg once daily in the morning [qAM]) compared to placebo. A single-blind reference treatment of 2000 mg metformin immediate-release (Met IR) per day administered as equal divided doses (1000 mg Met IR BID) will also be included.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose treatment
600 mg metformin delayed-release once daily in the morning
met dr
metformin delayed-release tablets
900 mg metformin delayed-release once daily in the morning
met dr
metformin delayed-release tablets
1200 mg metformin delayed-release once daily in the morning
met dr
metformin delayed-release tablets
1500 mg metformin delayed-release once daily in the morning
met dr
metformin delayed-release tablets
(Placebo Comparator)
placebo match for 600 and 1200 mg Met DR qAM treatment groups
(Placebo Comparator)
placebo match for 900 and 1500 mg Met DR qAM treatment groups
(Active Comparator)
1000 mg metformin immediate-release twice daily
met ir
metformin immediate-release tablets

Primary Outcomes

Change in HbA1c (%) at 16 Weeks
time frame: Baseline and 16 weeks after the first dose of study medication

Eligibility Criteria

Male or female participants at least 25 years old.

Inclusion Criteria: 1. Is at least 25 years old at Visit 1 (Screening). 2. Is male, or is female and meets all of the following criteria: 1. Not breastfeeding 2. Negative pregnancy test result at Visit 1 (not applicable to post-menopausal or surgically sterile females) 3. Surgically sterile, postmenopausal, or if of childbearing potential, must practice and be willing to continue to practice appropriate birth control during the entire duration of the study. 3. Body mass index (BMI) 20.0 to 45.0 kg/m² (inclusive) at Visit 1 (Screening). 4. Has a physical examination with no clinically significant abnormalities as judged by the investigator. 5. Has T2DM and an HbA1c of 7.5% to 10.5%, inclusive, at Visit 1. 6. Has an estimated glomerular filtration rate (eGFR) value of ≥60 mL/min/1.73 m² based on the Modification of Diet in Renal Disease (MDRD) equation. 7. Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 3 months prior to Visit 1: 1. Thiazolidinedione, sulfonylurea, dipeptidyl peptidase-4 inhibitors, and alpha-glucosidase inhibitors 2. Hormone replacement therapy (female subjects) and testosterone (male subjects) 3. Oral contraceptives (female subjects) 4. Antihypertensive agents 5. Lipid-lowering agents 6. Thyroid replacement therapy 7. Antidepressant agents 8. Ability to understand and willingness to adhere to protocol requirements. Exclusion Criteria: 1. Has a clinically significant medical condition as judged by the investigator that could potentially affect study participation and/or personal well-being, including but not limited to the following conditions: 1. Hepatic disease 2. Gastrointestinal disease 3. Endocrine disorder (T2DM is allowed) 4. Cardiovascular disease 5. Central nervous system diseases 6. Psychiatric or neurological disorders 7. Organ transplantation 8. Chronic or acute infection 9. Orthostatic hypotension, fainting spells or blackouts 10. Allergy or hypersensitivity. 2. A history of diabetic ketoacidosis or hyperosmolar non-ketotic hyperglycemia within the past year. 3. Prior major surgery of any kind within 6 months of Visit 1. 4. A history of >3% weight change within 3 months of Visit 1. 5. A clinical laboratory test (clinical chemistry, hematology, or urinalysis) abnormality, other than that related to T2DM, judged by the investigator to be clinically significant at Visit 1. 6. An alanine aminotransferase or aspartate aminotransferase result >2.5 × upper limit of normal (ULN) or a bilirubin result >1.5 × ULN. 7. A physical, psychological, or historical finding that, in the investigator's opinion, would make the subject unsuitable for the study. 8. Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following excluded medications: 1. Metformin within 2 months of Visit 1 (Screening) 2. Insulin within 2 weeks of Visit 1 (Screening) or for more than 1 week within 3 months of Visit 1 (Screening) 3. Glucagon-like peptide-1 receptor agonists or sodium-glucose co-transporter 2 inhibitors within 3 months of Visit 1 4. Drugs known to affect body weight, including prescription medications and over-the-counter anti obesity agents within 3 months of Visit 1. 5. Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have a high rate of systemic absorption within 3 months of Visit 1 6. Planned use of any drug treatment that affects gastric pH (prescription or over-the-counter), such as H2-receptor antagonists and proton pump inhibitors, after Visit 2 (Week -2), or planned chronic use of any antacids (i.e., more than twice per week) after Visit 2 (Week -2) 7. Cationic drugs that are eliminated by renal tubular secretion within 1 week of Visit 1. 8. Iodinated contrast dye within 1 week prior to Visit 1. 9. Investigational drug within 2 months (or five half-lives of the investigational drug, whichever is greater) of the date of the first dose of randomized study medication. 10. Met DR or double-blind matching placebo for Met DR at any time prior to Visit 1 (Screening) 9. Currently abuses drugs or alcohol or has a history of abuse that in the investigator's opinion would cause the individual to be noncompliant with study procedures. 10. Had a blood transfusion or experienced significant blood loss (i.e., >500 mL), including loss due to blood donation, within 2 months prior to Visit 1 (Screening), or is planning to donate blood during the study. 11. Has known immune system based allergies or hypersensitivity to any component of study treatment. A history of gastrointestinal intolerance to metformin is not exclusionary. 12. Is employed by Elcelyx Therapeutics, Inc. (that is an employee, contract worker, or designee of the company). 13. Has a fasting plasma glucose value >270 mg/dL at Visit 1 (Screening), Visit 2 (Week -2), and an unscheduled visit to be completed within 1 week following Visit 2. The unscheduled visit is to be completed only for subjects with a fasting plasma glucose value >270 mg/dL at Visit 1 and Visit 2.

Additional Information

Official title Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled, Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release In Subjects With Type 2 Diabetes Mellitus
Principal investigator Juan P Frias, MD
Trial information was received from ClinicalTrials.gov and was last updated in May 2016.
Information provided to ClinicalTrials.gov by Elcelyx Therapeutics, Inc..